Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 03, 2016 08:00 ET | Source: Zogenix, Inc.

Zogenix to Participate in LEERINK Partners 5th Annual Global Healthcare Conference

EMERYVILLE, Calif., Feb. 03, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today...
January 19, 2016 08:00 ET | Source: Zogenix, Inc.

Zogenix Receives Fast Track Designation From FDA for Development of ZX008 in Dravet Syndrome

EMERYVILLE, Calif., Jan. 19, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today...
January 11, 2016 08:00 ET | Source: Zogenix, Inc.

Zogenix Announces Initiation of Phase 3 Program for ZX008 in Dravet Syndrome

SAN DIEGO, Jan. 11, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced...
December 14, 2015 08:00 ET | Source: Zogenix, Inc.

Zogenix Announces FDA Acceptance of Investigational New Drug Application for ZX008 Phase 3 Clinical Trial in Dravet Syndrome

SAN DIEGO, Dec. 14, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced...
December 07, 2015 08:00 ET | Source: Zogenix, Inc.

Zogenix Announces New Efficacy and Safety Data on ZX008 for Treatment of Seizures in Dravet Syndrome

SAN DIEGO, Dec. 7, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced new...
November 25, 2015 08:00 ET | Source: Zogenix, Inc.

New Data on Zogenix's ZX008 for Dravet Syndrome to be Presented at 69th Annual American Epilepsy Society Meeting

Three Poster Presentations will Highlight Efficacy, Cardiovascular Safety and Mechanism of Action of Low-Dose Fenfluramine in the Treatment of Dravet Syndrome Zogenix will also Host a Scientific...
November 11, 2015 08:00 ET | Source: Zogenix, Inc.

Zogenix to Participate in Stifel 2015 Healthcare Conference

SAN DIEGO, Nov. 11, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced...
November 09, 2015 16:01 ET | Source: Zogenix, Inc.

Zogenix Provides Corporate Update and Reports Third Quarter 2015 Financial Results

SAN DIEGO, Nov. 9, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, provided a corporate...
November 02, 2015 08:00 ET | Source: Zogenix, Inc.

Zogenix to Release Third Quarter 2015 Financial Results and Host Conference Call & Webcast on November 9

SAN DIEGO, Nov. 2, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that...
October 19, 2015 16:01 ET | Source: Zogenix, Inc.

Zogenix Provides Regulatory Update for ZX008

SAN DIEGO, Oct. 19, 2015 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced the...

keyboard_arrow_left Previous Page